M&A Solutions/DD
Providing full-life cycle solutions for MAH project
M&A Solutions/DD

With the deepening of China's institutional reform of pharmaceutical enterprises and the adjustment of industrial structure, many pharmaceutical enterprises have begun to pay attention to the construction of a complete industrial chain to enhance their core competitiveness, pursue high-quality development strategies, and to achieve a large-scale, intensive, and international business objective via Merger and Acquisition (M&A).

In the past years, Canny has supported for many "M&A Risk Avoidance and Compliance Solutions" project for MNC and local companies to assist for regulatory compliance assessment and risks avoidance during the M&A process by sending our experts to support for Due Diligence for the aspect of regulatory Affairs compliance and GMP compliance.

CANNY-Your Trustworthy Consultant for Drug Regulatory Compliance!
  • 25 years
    of professional consulting experience in the pharmaceutical industry
  • 700 +
    GMP certification projects for China, EU, FDA, UK, Japan, Australia and WHO inspection
  • 320 +
    Validation execution and guidance projects
  • 2400 +
    Globally RA registration projects
  • 1370 +
    Globally clients and pharmaceutical partners
  • 30 +
    Experts from China, US and EU
Professional Services, Standardized SOPs

Providing full-life cycle solutions for MAH project

If you have business needs
Contact Us